Overview

Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy. METHODS: 71 elderly stable, compensated HFPEF patients (age 70+1 years; 80% women) with controlled blood pressure were randomized into a 12 month follow-up (FU) double-blind trial of enalapril 20 mg per day (E) vs. placebo (P). Assessments included: peak exercise oxygen consumption (VO2); six-minute walk test; Minnesota Living with HF Questionnaire (MLHF); MRI; Doppler-echocardiography; and vascular ultrasound.
Phase:
Phase 3
Details
Lead Sponsor:
Wake Forest University
Wake Forest University Health Sciences need to be deleted
Treatments:
Enalapril
Enalaprilat